CABAZITAXEL

Search structure
Trade Names:
Synonyms:
Status: Approved (2010)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L01CD04
UNII: 51F690397J

Structure
InChI Key BMQGVNUXMIRLCK-OAGWZNDDSA-N
Smile CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C
InChI
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C45H57NO14
Molecular Weight 835.94
AlogP 4.57
Hydrogen Bond Acceptor 14.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 10.0
Polar Surface Area 202.45
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 60.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Tubulin inhibitor DailyMed Wikipedia

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 4 D064129 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Liposarcoma 2 D008080 ClinicalTrials
Carcinoma, Transitional Cell 2 D002295 ClinicalTrials
Penile Neoplasms 2 D010412 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Adrenal Cortex Neoplasms 2 D000306 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Small Cell Lung Carcinoma 2 D055752 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Testicular Neoplasms 2 D013736 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Brain Neoplasms 1 D001932 ClinicalTrials
Glioma 1 D005910 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Blood and lymphatic system disorders Anaemia 97.3
Blood and lymphatic system disorders Leukopenia 95.6
Blood and lymphatic system disorders Neutropenia 93.5
Blood and lymphatic system disorders Neutropenia 82.0
Blood and lymphatic system disorders Neutropenia 81.7
Blood and lymphatic system disorders Leukopenia 69.0
Blood and lymphatic system disorders Leukopenia 68.2
Blood and lymphatic system disorders Neutropenia 58.0
Blood and lymphatic system disorders Thrombocytopenia 47.4
Gastrointestinal disorders Diarrhoea 46.6
Blood and lymphatic system disorders Leukopenia 42.0
Blood and lymphatic system disorders Anaemia 11.0
Blood and lymphatic system disorders Anaemia 10.5
Blood and lymphatic system disorders Febrile neutropenia 7.5
Blood and lymphatic system disorders Febrile neutropenia 7.0
Gastrointestinal disorders Diarrhoea 6.2
Gastrointestinal disorders Diarrhoea 6.0
Blood and lymphatic system disorders Anaemia 5.0
General disorders and administration site conditions Asthenia 5.0
General disorders and administration site conditions Fatigue 5.0
Musculoskeletal and connective tissue disorders Back pain 4.0
Blood and lymphatic system disorders Thrombocytopenia 4.0
General disorders and administration site conditions Asthenia 3.0
Musculoskeletal and connective tissue disorders Back pain 3.0
General disorders and administration site conditions Fatigue 3.0
Gastrointestinal disorders Abdominal pain 2.0
General disorders and administration site conditions Asthenia 2.0
Metabolism and nutrition disorders Dehydration 2.0
Gastrointestinal disorders Gastrointestinal pain 2.0
Renal and urinary disorders Haematuria 2.0
Gastrointestinal disorders Nausea 2.0
Blood and lymphatic system disorders Neutropenia 2.0
General disorders and administration site conditions Pain 2.0
Blood and lymphatic system disorders Thrombocytopenia 2.0
Infections and infestations Urinary tract infection 2.0
Gastrointestinal disorders Vomiting 2.0
Infections and infestations Septic shock 1.1
Cardiac disorders Arrhythmia 1.0
Musculoskeletal and connective tissue disorders Arthralgia 1.0
Investigations Body temperature increased 1.0
Gastrointestinal disorders Constipation 1.0
General disorders and administration site conditions Decreased appetite 1.0
Metabolism and nutrition disorders Dehydration 1.0
Gastrointestinal disorders Diarrhoea 1.0
Cardiac disorders Dizziness 1.0
Cardiac disorders Dyspnoea 1.0
Blood and lymphatic system disorders Febrile neutropenia 1.0
Renal and urinary disorders Haematuria 1.0
Vascular disorders Hypotension 1.0
General disorders and administration site conditions Mucosal inflammation 1.0
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 1.0
Gastrointestinal disorders Nausea 1.0
Nervous system disorders Neuropathy peripheral 1.0
Cardiac disorders Oedema peripheral 1.0
General disorders and administration site conditions Pain 1.0
Infections and infestations Urinary tract infection 1.0
Investigations Weight decreased 1.0
Blood and lymphatic system disorders Neutropenic sepsis 0.8
Infections and infestations Infection 0.5

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
13.98
Respiratory, thoracic and mediastinal disorders
9.34
Blood and lymphatic system disorders
8.88
Vascular disorders
8.7
Gastrointestinal disorders
7.7
Investigations
7.59
Nervous system disorders
6.09
Infections and infestations
5.76
Renal and urinary disorders
5.01
Cardiac disorders
4.68
Metabolism and nutrition disorders
3.83
Musculoskeletal and connective tissue disorders
2.71
Injury, poisoning and procedural complications
2.64
Eye disorders
2.54
Skin and subcutaneous tissue disorders
2.04

Cross References

Resources Reference
CAS NUMBER 183133-96-2
ChEBI 63584
ChEMBL CHEMBL1201748
DrugBank DB06772
DrugCentral 4153
EPA CompTox DTXSID40171389
FDA SRS 51F690397J
Human Metabolome Database HMDB0015672
Guide to Pharmacology 6798
PharmGKB PA165958401
PubChem 9854073
SureChEMBL SCHEMBL179674
ZINC ZINC000085536932
CONTENTS